Form 8-K Filing - Becton, Dickinson and Company

Becton, Dickinson and Company (BD) has resumed shipment of ChloraPrep™ in the U.S. after placing the product on a voluntary ship hold on May 6, 2026, for additional final release testing. This action was taken in response to a Warning Letter from the FDA concerning the El Paso manufacturing facility. BD has completed additional assessments and initiated final release testing, confirming that all testing has been acceptable and that no patient safety issues have arisen. The company is working to ensure continuity of patient care. Further details regarding the El Paso Warning Letter and associated risks can be found in BD's Form 10-Q for the period ended March 31, 2026, and other SEC filings.